Carregant...
Fitxers
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/224705
A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
TheP2X7receptorisanATP-gated ion channel that activates inflammatory pathways involved in diseases such as cancer, atherosclerosis, and neurodegeneration. However, despite the potential benefits of blocking overactive signaling, no P2X7 receptor antagonists have been approved for clinical use. Understanding species-specific pharmacological effects of existing antagonists has been challenging, in part due to the dearth of molecular information on receptor orthologs. Here, to identify distinct molecular features in the human receptor, we determine high-resolution cryo-EM structures of the fulllength wild-type human P2X7 receptor in apo closed and ATP-bound open state conformationsanddrawcomparisonswithstructuresofotherorthologs. Wealso report a cryo-EM structure of the human receptor in complex with an adamantane-based inhibitor, which we leverage, in conjunction with functional data and molecular dynamics simulations, to design a potent and selective antagonist with a unique polycyclic scaffold. Functional and structural analysis reveal how this optimized ligand, termed UB-MBX-46, interacts with the classical allosteric pocket of the human P2X7 receptor with subnanomolar potency and high selectivity, revealing its significant therapeutic potential.
Matèries
Matèries (anglès)
Citació
Citació
KIM, Yong-chul, MÜLLER, Christa e., KOLOCOURIS, Antonios, VÁZQUEZ CRUZ, Santiago, MANSOOR, Steven e, OKEN, Adam c., TURCU, Andreea l., TZORTZINI, Eva, GEORGIOU, Kyriakos, NAGEL, Jessica, WESTERMANN, Franka g., BARNIOL-XICOTA, Marta, SEIDLER, Jonas, KIM, Ga-ram, LEE, So-deok, NICKE, Annette. A polycyclic scaffold identified by structure-based drug design effectively inhibits the human P2X7 receptor. _Nature Communications_. 2025. Vol. 16, núm. 8283. [consulta: 3 de gener de 2026]. ISSN: 2041-1723. [Disponible a: https://hdl.handle.net/2445/224705]